Initial experience with vitamin D3 supplementation on cognitive function in NPSLE patients in Bangladesh
Nutrition and Health · 2026-11 · 32 (6) · 2019-2029
DOI: 10.1177/02601060251410451 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrition and Health, online erschienen am 08.01.2026. Verfasst von Nasreen Sultana und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Nuclear Medicine and Allied Sciences, Bangladesh Atomic Energy Commission (BAEC), Dhaka, Bangladesh. Hauptthemen laut MEDLINE: Cholecalciferol, Cognition, Cognitive Dysfunction, Dietary Supplements. Die Arbeit nennt 36 Literaturangaben. Gefördert von: International atomic energy agency.
Abstract (Originalsprache)
Background
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease often affecting the central nervous system, resulting in neuropsychiatric SLE (NPSLE). Cognitive dysfunction, a common manifestation, significantly impacts quality of life. Vitamin D3, recognized for its neuroprotective and cognitive-enhancing properties, is a potential therapeutic option for NPSLE.
Objectives
This randomized controlled trial (RCT) evaluates the effects of vitamin D3 supplementation on cognitive function in NPSLE patients.
Methods
NPSLE patients ( N = 72) of standard SLE care were allocated into an intervention group ( n = 34) receiving vitamin D3 (40,000 IU) supplementation/week for 6 weeks, then 2000 IU/day for 3 months, and a control group ( n = 38) without vitamin D3. Serum vitamin D3 concentration, mini-mental state examination (MMSE) scores, and brain hypo-perfusion images by single-photon emission computed tomography (SPECT) were obtained at baseline and after 6 months of follow-up.
Results
Baseline characteristics (age, gender, BMI, waist-to-hip-ratio) were independent between groups. After the intervention, concentration of vitamin D3 (ng/mL) rose from 16.2 ± 4.9 to 28.3 ± 5.3 within the “intervention group” ( P ≤ 0.001). Similarly, the mean differences of MMSE scores were significantly higher in Cases than Controls (2.2 vs. 0.3). Analysis of covariance (ANCOVA) revealed large effect sizes for vitamin D concentration (η 2 p = 0.714) and medium effect sizes (η 2 p = 0.460) for MMSE scores. Furthermore, an insignificant ( P > 0.05) shift (moderate to mild) of brain hypo-perfusion level was observed over time.
Conclusion
Vitamin D3 supplementation effectively increased serum vitamin D concentration by supporting its role as an adjunctive therapy in NPSLE patients, leading to improvements in cognitive function and brain perfusion levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Institute of Nuclear Medicine and Allied Sciences, Bangladesh Atomic Energy Commission (BAEC), Dhaka, Bangladesh.
- Department of Electrical and Electronic Engineering, Jamalpur Science and Technology University, Melandaha, Bangladesh.
- Institute of Nutrition and Food Sciences, University of Dhaka, Dhaka, Bangladesh.
ORCID-Profile: Nasreen Sultana, Mahbuba Kawser
Förderung
- International atomic energy agency
Zitieren
APA
Sultana, N., Ihsan, M. A., Adnan, S. M., Kawser, M., Arefin, M. S., & Islam, S. N. (2026). Initial experience with vitamin D3 supplementation on cognitive function in NPSLE patients in Bangladesh. Nutrition and Health, 32(6), 2019-2029. https://doi.org/10.1177/02601060251410451
Vancouver
Sultana N, Ihsan MA, Adnan SM, Kawser M, Arefin MS, Islam SN. Initial experience with vitamin D3 supplementation on cognitive function in NPSLE patients in Bangladesh. Nutrition and Health. 2026;32(6):2019-2029. doi:10.1177/02601060251410451
BibTeX
@article{Sultana2026,
author = {Sultana, Nasreen and Ihsan, Md Amimul and Adnan, Sheikh Md and Kawser, Mahbuba and Arefin, Md Saidul and Islam, Sheikh Nazrul},
title = {Initial experience with vitamin D3 supplementation on cognitive function in NPSLE patients in Bangladesh},
journal = {Nutrition and Health},
year = {2026},
volume = {32},
number = {6},
pages = {2019--2029},
doi = {10.1177/02601060251410451}
}
EUVIMED